Literature DB >> 19914987

City leadership for health and sustainable development: the World Health Organization European Healthy Cities Network.

Agis Tsouros1.   

Abstract

This paper provides an overview of European Healthy Cities Network (EHCN) organized by the WHO Regional Office Europe. The focus is on the third of five phases covering the period 1998-2002. Fifty-six cities were members of the WHO-EHCN and over 1000 European cities were members of national networks. Association with WHO has given municipalities legitimacy to move into a domain often associated with health service. Equity and community participation are core values. City mayors provide political leadership. Intersectoral cooperation underpins a Healthy Cities approach. The WHO Regional Office for Europe supports WHO-EHCN, providing guidance and technical leadership. Cities' processes and structures are prerequisits for improvements in health and are central to the evaluation of Phase III of the WHO-EHCN.

Mesh:

Year:  2009        PMID: 19914987     DOI: 10.1093/heapro/dap050

Source DB:  PubMed          Journal:  Health Promot Int        ISSN: 0957-4824            Impact factor:   2.483


  4 in total

1.  Evaluation of partnership working in cities in phase IV of the WHO Healthy Cities Network.

Authors:  Alistair Lipp; Tim Winters; Evelyne de Leeuw
Journal:  J Urban Health       Date:  2013-10       Impact factor: 3.671

2.  City leadership for health and well-being: back to the future.

Authors:  Agis Tsouros
Journal:  J Urban Health       Date:  2013-10       Impact factor: 3.671

3.  Evaluating WHO Healthy Cities in Europe: issues and perspectives.

Authors:  Evelyne de Leeuw
Journal:  J Urban Health       Date:  2013-10       Impact factor: 3.671

4.  Gender Differences in Association between Air Pollution and Daily Mortality in the Capital of the Green Lungs of Poland-Population-Based Study with 2,953,000 Person-Years of Follow-Up.

Authors:  Łukasz Kuźma; Krzysztof Struniawski; Szymon Pogorzelski; Hanna Bachórzewska-Gajewska; Sławomir Dobrzycki
Journal:  J Clin Med       Date:  2020-07-23       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.